The increasing prevalence of drug-resistant bacterial infections demands the development of new antibacterials that are not subject to existing mechanisms of resistance. Previously, we described coumarin-based inhibitors of an underexploited bacterial target, namely the replicative helicase. Here we report the synthesis and evaluation of optimized coumarin-based inhibitors with 9-18-fold increased potency against Staphylococcus aureus (Sa) and Bacillus anthracis (Ba) helicases. Compounds 20 and 22 provided the best potency, with IC(50) values of 3 and 1 μM, respectively, against the DNA duplex strand-unwinding activities of both B. anthracis and S. aureus helicases without affecting the single strand DNA-stimulated ATPase activity. Selectivity index (SI = CC(50)/MIC) values against S. aureus and B. anthracis for compound 20 were 33 and 66 and for compound 22 were 20 and 40, respectively. In addition, compounds 20 and 22 demonstrated potent antibacterial activity against multiple ciprofloxacin-resistant MRSA strains, with MIC values ranging between 0.5 and 4.2 μg/mL.
The increasing prevalence of drug-resistant bacterial infections demands the development of new antin class="Species">bacterials that are not subject to existing mechanisms of resistance. Previously, we described coumarin-based inhibitors of an underexploited bacterial target, namely the replicative helicase. Here we report the synthesis and evaluation of optimized coumarin-based inhibitors with 9-18-fold increased potency against Staphylococcus aureus (Sa) and Bacillus anthracis (Ba) helicases. Compounds 20 and 22 provided the best potency, with IC(50) values of 3 and 1 μM, respectively, against the DNA duplex strand-unwinding activities of both B. anthracis and S. aureushelicases without affecting the single strand DNA-stimulated ATPase activity. Selectivity index (SI = CC(50)/MIC) values against S. aureus and B. anthracis for compound 20 were 33 and 66 and for compound 22 were 20 and 40, respectively. In addition, compounds 20 and 22 demonstrated potent antibacterial activity against multiple ciprofloxacin-resistant MRSA strains, with MIC values ranging between 0.5 and 4.2 μg/mL.
Authors: Karin Loscha; Aaron J Oakley; Bogdan Bancia; Patrick M Schaeffer; Pavel Prosselkov; Gottfried Otting; Matthew C J Wilce; Nicholas E Dixon Journal: Protein Expr Purif Date: 2004-02 Impact factor: 1.650
Authors: Bing Li; Ramdas Pai; Daniel Aiello; Ming Di; Marjorie H Barnes; Norton P Peet; Terry L Bowlin; Donald T Moir Journal: Bioorg Med Chem Lett Date: 2013-04-30 Impact factor: 2.823
Authors: Mina Saeedi; Fereshteh Goli; Mohammad Mahdavi; Gholamreza Dehghan; Mohammad Ali Faramarzi; Alireza Foroumadi; Abbas Shafiee Journal: Iran J Pharm Res Date: 2014 Impact factor: 1.696